Press Releases Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
1.09 ^USD	-2.68%		-13.49%	+98.18%

Apr. 19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
Apr. 01	Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results	07:30am	GL
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results	Apr. 01	GL
Xilio Therapeutics : Corporate Update Call	Mar. 28	PU
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing	Mar. 28	GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	Mar. 28	GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	Mar. 28	AQ
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference	Feb. 28	GL
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference	Feb. 28	AQ
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference	Jan. 31	GL
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference	Jan. 31	AQ
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies	Jan. 08	GL
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies	Jan. 08	AQ
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data	Dec. 07	GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results	Nov. 09	GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results	Nov. 09	AQ
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors	Nov. 03	GL
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors	Nov. 03	AQ
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023	Nov. 01	AQ
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting	23-10-31	GL
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's 38th Annual Meeting	23-09-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Press Releases

Filters